Uludag University, Medical School, Department of Medical Biochemistry, Bursa, Turkey.
Eur J Med Chem. 2011 Oct;46(10):4957-63. doi: 10.1016/j.ejmech.2011.07.055. Epub 2011 Aug 5.
Anti-cancer effects of a newly-synthesized palladium(II) complex, Pd(sac)(terpy)·4H(2)O (sac = saccharinate, and terpy = 2,2':6',2''-terpyridine), were tested against human breast cancer cell lines, MCF-7 and MDA-MB-231. The Pd complex had a strong anti-growth effect in a dose- and time-dependent manner in vitro. This effect was also confirmed by the experiment performed on Balb/c mice in vivo. The IC(50) values were 0.09 μM for MDA-MB-231 and 3.05 μM for MCF-7. It was also very effective in disrupting the formation of MDA-MB-231 tubules on matrigel, indicative of a putative anti-invasive activity. It induced apoptosis via the cell death genes of DR4 and DR5. In conclusion, this newly-synthesized Pd (II) complex represents a potentially active novel drug for the breast cancer treatment.
新型钯(II)配合物[Pd(sac)(terpy)]·4H2O(sac= saccharinate,terpy=2,2':6',2''-三联吡啶)的抗癌作用被测试用于人乳腺癌细胞系 MCF-7 和 MDA-MB-231。该钯配合物在体外具有很强的剂量和时间依赖性的抗生长作用。体内 Balb/c 小鼠实验也证实了这一效果。IC50 值为 0.09 μM 的 MDA-MB-231 和 3.05 μM 的 MCF-7。它在破坏 Matrigel 上 MDA-MB-231 小管的形成方面也非常有效,表明具有潜在的抗侵袭活性。它通过 DR4 和 DR5 的细胞死亡基因诱导细胞凋亡。总之,这种新合成的钯(II)配合物代表了一种用于乳腺癌治疗的潜在有效新型药物。